1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
A Product and Pipeline Analysis of the Lung Cancer Therapeutics Market : Discovery of New Targeted Therapies will Replace Conventional Therapies

A Product and Pipeline Analysis of the Lung Cancer Therapeutics Market : Discovery of New Targeted Therapies will Replace Conventional Therapies

  • January 2015
  • 74 pages
  • ID: 2657747
  • Format: PDF
  • By Frost & Sullivan


Table of Contents

Executive Summary

•The estimated market size for lung cancer therapeutics in 2014 was $ x billion.
•There is increasing competition in this market, especially amongst the large pharmaceutical (pharma) participants such as Merck, AstraZeneca, Eli Lilly, and Bristol-Myers Squibb (BMS), which are set to launch their targeted therapy drugs.
•BMS has already launched Opdivo (Nivolumab) in Japan (July 2014), and became the first company to introduce its candidate in the ‘PD-L1’ pathway.
•Other mutations found in non-small cell lung cancer (NSCLC) such as EGFR ( x – %*), ALK ( x – %*), BRAF ( x – %*), HER ( x – %*), and KRAS ( x – %*) have only a few drugs in the pipeline.
•EGFR and ALK are the only two mutations that have FDA-approved drugs in the market.
•Two drugs targeting the ALK mut+ population are in the pipeline and have been given breakthrough therapy status by the Food and Drug Administration (FDA).
•Having faced failure as a potential target for a long time, KRAS mut+ NSCLC now has drugs in Phase-2 development.
•Squamous NSCLC, which constitutes x % of lung cancer patients worldwide, remains a condition with largely unmet needs due to the existence of very few approved targeted therapies for its treatment. Similarly, there is only one FDA-approved drug for third-line treatment of lung cancer, which is Tarceva.
•First-line treatment consists of administering the usual chemotherapy, i.e., platinum agent plus Gemcitabine, or Paclitaxel. However, this might change with the introduction of necitumumab, Eli Lilly’s candidate at present in Phase 3 of clinical trials in the United States.
•Other drugs such as Yervoy and nivolumab are also being tested in clinical trials as targeted therapy for squamous NSCLC.
•With a heavy pipeline of about x drugs in Phase-2 clinical trials, and most Phase-3 drugs showing effective results, a number of launches are expected by 2020.
•Tobacco consumption is the main cause of lung cancer worldwide, with approximately x % of the patients being smokers. Recent statistics show that x % of adults in China smoke regularly, and almost one in two men consume cigarettes regularly.
oIn addition, a less proactive take by the Chinese Government in raising lung cancer awareness contributes to making China the highest-growing market for lung cancer therapeutics today.
•A number of niche participants such as BioNumerik Pharmaceuticals, Ora Bio, Simcere Pharmaceutical Group, Peregrine Pharmaceuticals, RECOMBIO, Oncothyreon Inc., Tesaro Inc., Exelixis Inc., CureVac GmbH, Clovis Oncology, ArQule, NewLink Genetics Corporation, and Synta Pharmaceuticals have drugs in Phase 2 or Phase 3 in the pipeline for lung cancer treatment.

Methodology and Scope

•This research service focuses on the prescription drugs used for the treatment of both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). It does not cover non-pharmaceutical palliative therapies such as radiation and surgery.
•A product and pipeline assessment is provided for marketed and investigational products for the treatment of NSCLC and SCLC. Segmentation by drug class is provided, along with additional supporting information such as clinical trial timelines and results, projected launch timelines, and epidemiology.
•The information contained in this research service was derived from published sources, including disease organization Web sites; public health organization Web sites; company publications including annual reports, SEC filings, and press releases; government public sources; and published articles in scientific journals.


•Alkaloids are nitrogen-containing basic compounds mainly derived from animal and plant sources. Various alkaloids are used as therapeutic agents to inhibit cell reproduction; sometimes, they may even kill the cancerous cells. E.g., Abraxane®
•Cytostatics inhibit the proliferation of cells. In other words, these compounds inhibit the cancerous cells from growing, without killing them. Most cancer drugs fall into this category.
•Anti-angiogenics, or angiogenic inhibitors, are the class of cancer drugs that stop the growth of new blood vessels in cancerous tumours, thereby stopping their nourishment and their spread to other parts of the body.
•Anti-neoplastics, also know as anti-neoplastic chemotherapeutic drugs, destroy neoplastic cells in the body, which accumulate to form the cancerous tumours. However, they have the side-effect of destroying normal cells as well, thereby leaving the patient weak.
•Other Therapies*
oBone-calcium regulators do not treat the disease but are used in cases where the cancer has metastasized to the bone, leading to fractures and pain.
oCytotoxic antibiotics work by interfering with the DNA but do not directly lead to apoptosis and are sufficient for the body’s immune system to recognize and kill the cells.
oAnti-cancer agents selectively target cancer cells by detecting their altered metabolism from the normal cells in the body.
oImmunostimulants positively regulate the body’s immune system to fight the abnormal, cancerous cells.
oAnti-rheumatics act by stopping the recruitment of lymphocytes during inflammation in rheumatoid arthritis and, in case of cancer, towards the tumour.
oAlkylating agents are the oldest form of treatment for cancer. These drugs add an alkyl group to the DNA of cancerous cells, thereby hampering cell growth.
oAnti-metabolites disrupt the biosynthesis of nucleic acids, essential for the formation of DNA and RNA, thus leading to cell death.

Companies to Watch

•Has x drug candidates in the pipeline (Phase 2 and Phase 3), and one marketed product (Iressa) for lung cancer treatment.
•Plans to file AZD9291 for approval with the FDA in Q2 2015; this is one of the leading products for lung cancer R&D in the market.
•MEDI4736, a drug targeting the PD-1 pathway, recently entered Phase-3 clinical trials.

Ariad Pharmaceuticals
•AP26113 received breakthrough therapy status from the FDA in October 2014. Ariad plans to file the drug with the FDA in early 2016.
•Ariad’s share rose by % immediately after the FDA gave AP26113 breakthrough therapy status.

Roche Group
•Has 2 marketed products and 4 drugs in Phase 3 of clinical trials for lung cancer.
•Launched a Web site and a mobile app for lung cancer support and awareness in May 2014: www.pioneeringhealthcare.com/lung-cancer/
•Alecitinib, which targets ALK+ NSCLC, was approved for marketing in Japan in July 2014. It already has breakthrough therapy designation from the FDA.

Eli Lilly and Company
•Has 2 marketed, 2 filed with the FDA for approval, and 3 drugs in the pipeline (Phase 1 and Phase 2).
•Necitumumab has the potential to be the first targeted therapy for first-line treatment of squamous NSCLC.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Anaplastic Oligoastrocytoma - Pipeline Review, H2 2019

Anaplastic Oligoastrocytoma - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Anaplastic Oligoastrocytoma - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic Oligoastrocytoma - Pipeline Review, H2 2019, provides an overview ...

Bone Metastasis - Pipeline Review, H2 2019

Bone Metastasis - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Bone Metastasis - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Bone Metastasis - Pipeline Review, H2 2019, provides an overview of the Bone Metastasis ...

Merkel Cell Carcinoma - Pipeline Review, H2 2019

Merkel Cell Carcinoma - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Merkel Cell Carcinoma - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Merkel Cell Carcinoma - Pipeline Review, H2 2019, provides an overview of the Merkel ...


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on